US clears AstraZeneca’s $39bn acquisition of Alexion

AstraZeneca’s proposed $39 billion acquisition of Alexion Pharmaceuticals has achieved an important step toward completion having cleared US Federal Trade Commission review.

This follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

The announcement follows competition clearances in Canada, Brazil, Russia and other countries globally.

Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan.

These clearances further advance us towards closing our acquisition of Alexion,” said Marc Dunoyer, Executive Director and Chief Financial Officer of AstraZeneca.

“We remain focused on the next chapter for AstraZeneca and Alexion, building on our combined expertise in immunology and precision medicines and our shared ambition to bring more innovative medicines to patients worldwide.

“We look forward to working closely with other global authorities as we progress toward this goal.”

The proposed acquisition, first announced in December 2020, would enhance the company’s scientific presence in immunology by adding Alexion’s innovative complement-technology platforms and strong pipeline.

The acquisition remains expected to close in Q3 2021, subject to receipt of additional global regulatory clearances and approval by shareholders of both companies with shareholder voting anticipated on 11 May 2021.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news